A Multicenter, Open-label Phase I/II Clinical Study to Evaluate the Safety and Efficacy of Simmitinib or Irinotecan Liposomes Combined With DP303c Injection in the Treatment of HER2 Expressing Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT06577376

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-25T22:26:14.149760+00:00

Published At

2024-09-05T00:00:00+00:00

Record Updated At

2024-09-05

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma", "Expressing Human Epidermal Growth Factor Receptor-2 (HER-2)", "Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2024-09-05"

protocolSection.identificationModule.nctId

"NCT06577376"

protocolSection.identificationModule.officialTitle

"A Multicenter, Open-label Phase I/II Clinical Study to Evaluate the Safety and Efficacy of Simmitinib or Irinotecan Liposomes Combined With DP303c Injection in the Treatment of HER2 Expressing Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma"

protocolSection.statusModule.overallStatus

"NOT_YET_RECRUITING"

protocolSection.designModule.phases

["PHASE1", "PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Expressing Human Epidermal Growth Factor Receptor-2 (HER-2) (protocolSection.conditionsModule.conditions)
• Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.